Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 on red cells. The reactivity could be mistaken...

Full description

Bibliographic Details
Main Authors: Mei-Hwa Lin, Fei-Yun Liu, Hsiu-Mien Wang, Hsin-Ching Cho, Shyh-Chyi Lo
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Asian Journal of Transfusion Science
Subjects:
Antibody screen
daratumumab
pretransfusion testing
Online Access:http://www.ajts.org/article.asp?issn=0973-6247;year=2017;volume=11;issue=2;spage=209;epage=211;aulast=Lin

Similar Items

Similar Items